Format

Send to

Choose Destination
See comment in PubMed Commons below
Expert Opin Pharmacother. 2014 Aug;15(11):1601-10. doi: 10.1517/14656566.2014.930437. Epub 2014 Jul 3.

Guanfacine extended release for the treatment of attention-deficit/hyperactivity disorder in children and adolescents.

Author information

1
University of Connecticut School of Medicine and Health Care Center, Department of Psychiatry/MC1410 , 263 Farmington Avenue, Farmington, 06030-1410 CT , USA +1 860 679 2730 ; +1 860 679 4326 ; dconnor@uchc.edu.

Abstract

INTRODUCTION:

Guanfacine extended release (GXR) is a selective α(2A)-adrenoreceptor agonist originally developed as an antihypertensive agent and now FDA approved for the treatment of attention-deficit/hyperactivity disorder (ADHD) as monotherapy and as adjunctive to psychostimulants in children and adolescents 6-17 years old.

AREAS COVERED:

Search of the PubMed and PsycInfo databases from 1990 to 2014 using the search term 'guanfacine'. Studies selected for review were either controlled or open trials of guanfacine or GXR. Shire Pharmaceuticals, Inc. was contacted and supplied a synopsis of all available ADHD studies on GXR for review.

EXPERT OPINION:

GXR is an evidence-based treatment for ADHD in children and adolescents. Because this compound has a smaller effect size than psychostimulants for the symptoms of ADHD, it is generally considered a second-line treatment after the psychostimulants or in combination with psychostimulants. Evidence for efficacy is more robust in children than for adolescents. Because of its pharmacodynamic actions in prefrontal cortex, GXR shows considerable promise for other behavioral conditions frequently comorbid with ADHD and potential promise for emotional and behavioral dysregulation secondary to traumatic stress.

KEYWORDS:

attention deficit hyperactivity disorder; child; guanfacine extended release; α2A-adrenoreceptor agonist

PMID:
24992513
DOI:
10.1517/14656566.2014.930437
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Support Center